Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286134 | 0.99 | POLB (0.43) | POLBSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL22216157 | 0.97 | POLB (0.41) | POLBSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL22323003 | 0.94 | ALDH1A1 (0.40) | POLBSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL23000018 | 0.81 | TP53 (0.47) | SMN1; SMN2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL9685715 | 0.81 | POLB (0.39) | POLBSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL22999540 | 0.77 | FPR2 (0.42) | HPGDALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL1303947 | 0.77 | ALDH1A1 (0.39) | SMN1; SMN2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL3367604 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL22999965 | 0.76 | MEN1 (0.34) | HPGDALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL978323 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3892621-B1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-111434662-B | Haloallylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TransThera Sciences (Nanjing), Inc (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3892621-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892621-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020143763-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | 南京药捷安康生物科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | POLB 3715/4885SMN1; SMN2 339/4885HPGD 3251/4885 |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | ADRA1D, ADRA1A, VAPA | POLB 3715/4885SMN1; SMN2 339/4885HPGD 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.